title: Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome.
abstract: Circulating IgG-immune complexes (IgG-IC) play a role in the complex etiology of C-HUS. In an ongoing open clinical study protein A immunoadsorption treatment is carried out for patients who developed severe forms of the syndrome after mitomycin-C chemotherapy. So far, successful treatment of 14 out of 19 evaluable patients was possible. A protein A immunoadsorption system was used, allowing processing of large plasma volumes to eliminate IgG and IgG-IC from the patient's plasma.
authors.affiliation: Department of Hematology/Oncology (Tumor-Center Hanover), Germany.
authors.forename: E J
authors.initials: EJ
authors.lastname: Borghardt
authors.forename: E J
authors.initials: EJ
authors.lastname: Kirchertz
authors.forename: I
authors.initials: I
authors.lastname: Marten
authors.forename: K
authors.initials: K
authors.lastname: Fenchel
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000276:immunology*; D006801:Humans; D007163:Immunosorbent Techniques; D016685:Mitomycin / Q000009:adverse effects*; D013205:Staphylococcal Protein A / Q000302:isolation & purification*